TSE:PLB - Paladin Labs Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company's product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In July 2013, the Company became the sole holder of Allon Therapeutics Inc. In September 2013, Blackstar Group SE announced that it has sold remaining 13.4% interests in Litha Healthcare Group Limited (Litha) to Paladin Labs Inc. Effective January 1, 2014, Paladin Labs Inc. acquired Triton Pharma Inc.

Receive PLB News and Ratings via Email

Sign-up to receive the latest news and ratings for PLB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
Phone+1-514-3401112

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Paladin Labs (TSE:PLB) Frequently Asked Questions

What is Paladin Labs' stock symbol?

Paladin Labs trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLB."

Has Paladin Labs been receiving favorable news coverage?

News coverage about PLB stock has trended negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Paladin Labs earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Paladin Labs?

Shares of PLB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Paladin Labs' official website?

The official website for Paladin Labs is http://www.paladinlabs.com.

How can I contact Paladin Labs?

Paladin Labs' mailing address is 100 Alexis-Nihon Blvd Suite 600, SAINT-LAURENT, QC H4M 2P2, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-3401112.


MarketBeat Community Rating for Paladin Labs (TSE PLB)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Paladin Labs and other stocks. Vote "Outperform" if you believe PLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel